Literature DB >> 7196092

Susceptibility of Zygomycetes to human serum.

R H Eng, M Corrado, E Chin.   

Abstract

Seven members of the class Zygomycetes were tested for serum susceptibility. Five of the isolates were inhibited to different degrees by pooled fresh human serum. Heating the serum at 56 degrees C for 30 min to inactivate complement did not abolish the inhibitory activity in the serum. Members of the genera Cunninghamella and Absidia appeared most susceptable to the inhibitory effects of serum while members of the genus Rhizopus were most resistant. One isolate of R. arrhizus appeared to have enhanced growth in the presence of human serum. Our findings suggest certain species of the class Zygomycetes are strongly inhibited by serum, and this may account for the rarity of human infections by these species.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7196092     DOI: 10.1080/00362178185380171

Source DB:  PubMed          Journal:  Sabouraudia        ISSN: 0036-2174


  5 in total

1.  Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus.

Authors:  Anna H T Gifford; Jodine R Klippenstein; Margo M Moore
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Susceptibility of zygomycetes to amphotericin B, miconazole, and ketoconazole.

Authors:  R H Eng; A Person; C Mangura; H Chmel; M Corrado
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

3.  Disseminated zygomycosis due to Rhizopus schipperae after heatstroke.

Authors:  G M Anstead; D A Sutton; E H Thompson; I Weitzman; R A Otto; S K Ahuja
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

Review 4.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 5.  Opportunistic zygomycotic infections. A literature review.

Authors:  A Espinel-Ingroff; L A Oakley; T M Kerkering
Journal:  Mycopathologia       Date:  1987-01       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.